Matches in SemOpenAlex for { <https://semopenalex.org/work/W2536704472> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2536704472 endingPage "1549" @default.
- W2536704472 startingPage "1549" @default.
- W2536704472 abstract "1549 Background: Combination therapy using agents with different mechanisms of action and non-overlapping toxicity may be a safe and effective strategy in cancer therapy. As seen in Phase I of this trial, BID temozolomide [Temodar (TMZ)] in combination with celecoxib (Celebrex) is a safe treatment regimen for malignant glioma. Phase II of this clinical trial tests the hypothesis that celecoxib combined with a BID schedule of TMZ is a more effective therapy for recurrent/progressive malignant glioma. Methods: Patients received a loading dose of 200 mg/m2 of TMZ followed by 9 doses of 90 mg/m2 TMZ BID for 5 days of every 28 day cycle. Celecoxib was given to a maximum dose of 480 mg/m2 for 10 days. The regimen was well-tolerated by most patients. Hematologic toxicity was mild and did not recur following TMZ dose reduction. Results: 36 patients (22 M, 14 F) received 141 cycles of therapy. Interim responses were evaluated after 2 cycles. In the 29 patients evaluable for response, 5/29 (17%) had a partial response (PR), 21/29 (72.5%) had stable disease (SD), and 3/29 (10.5%) had progressive disease, resulting in an overall response rate of 90% at 2 months. One patient had a CR after 7 cycles. One patient had a PR for 13 cycles but developed spinal cord tumor. Average duration of response was 5.2 months (range, 2–13). The 6-month PFS for 23 evaluable patients was 8/23(35%) and 6-month overall survival rate of 19/23(83%). Conclusions: A regimen of twice-daily TMZ and celecoxib is a safe and potentially effective regimen for the treatment of recurrent high-grade glioma. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Schering-Plough" @default.
- W2536704472 created "2016-10-28" @default.
- W2536704472 creator A5013226690 @default.
- W2536704472 creator A5018718651 @default.
- W2536704472 creator A5046414791 @default.
- W2536704472 creator A5072070011 @default.
- W2536704472 creator A5075752889 @default.
- W2536704472 creator A5080490911 @default.
- W2536704472 date "2004-07-15" @default.
- W2536704472 modified "2023-10-14" @default.
- W2536704472 title "Phase I/II trial of a twice-daily regimen of temozolomide and celecoxib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma" @default.
- W2536704472 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.1549" @default.
- W2536704472 hasPublicationYear "2004" @default.
- W2536704472 type Work @default.
- W2536704472 sameAs 2536704472 @default.
- W2536704472 citedByCount "1" @default.
- W2536704472 crossrefType "journal-article" @default.
- W2536704472 hasAuthorship W2536704472A5013226690 @default.
- W2536704472 hasAuthorship W2536704472A5018718651 @default.
- W2536704472 hasAuthorship W2536704472A5046414791 @default.
- W2536704472 hasAuthorship W2536704472A5072070011 @default.
- W2536704472 hasAuthorship W2536704472A5075752889 @default.
- W2536704472 hasAuthorship W2536704472A5080490911 @default.
- W2536704472 hasConcept C126322002 @default.
- W2536704472 hasConcept C141071460 @default.
- W2536704472 hasConcept C143998085 @default.
- W2536704472 hasConcept C2776467144 @default.
- W2536704472 hasConcept C2776694085 @default.
- W2536704472 hasConcept C2777389519 @default.
- W2536704472 hasConcept C2778227246 @default.
- W2536704472 hasConcept C2778822529 @default.
- W2536704472 hasConcept C2778880634 @default.
- W2536704472 hasConcept C2779083369 @default.
- W2536704472 hasConcept C2781413609 @default.
- W2536704472 hasConcept C31760486 @default.
- W2536704472 hasConcept C502942594 @default.
- W2536704472 hasConcept C71924100 @default.
- W2536704472 hasConcept C90924648 @default.
- W2536704472 hasConceptScore W2536704472C126322002 @default.
- W2536704472 hasConceptScore W2536704472C141071460 @default.
- W2536704472 hasConceptScore W2536704472C143998085 @default.
- W2536704472 hasConceptScore W2536704472C2776467144 @default.
- W2536704472 hasConceptScore W2536704472C2776694085 @default.
- W2536704472 hasConceptScore W2536704472C2777389519 @default.
- W2536704472 hasConceptScore W2536704472C2778227246 @default.
- W2536704472 hasConceptScore W2536704472C2778822529 @default.
- W2536704472 hasConceptScore W2536704472C2778880634 @default.
- W2536704472 hasConceptScore W2536704472C2779083369 @default.
- W2536704472 hasConceptScore W2536704472C2781413609 @default.
- W2536704472 hasConceptScore W2536704472C31760486 @default.
- W2536704472 hasConceptScore W2536704472C502942594 @default.
- W2536704472 hasConceptScore W2536704472C71924100 @default.
- W2536704472 hasConceptScore W2536704472C90924648 @default.
- W2536704472 hasIssue "14_suppl" @default.
- W2536704472 hasLocation W25367044721 @default.
- W2536704472 hasOpenAccess W2536704472 @default.
- W2536704472 hasPrimaryLocation W25367044721 @default.
- W2536704472 hasRelatedWork W2032862134 @default.
- W2536704472 hasRelatedWork W2116440704 @default.
- W2536704472 hasRelatedWork W2283634263 @default.
- W2536704472 hasRelatedWork W2360510517 @default.
- W2536704472 hasRelatedWork W2410623908 @default.
- W2536704472 hasRelatedWork W2536704472 @default.
- W2536704472 hasRelatedWork W2589324256 @default.
- W2536704472 hasRelatedWork W2590053910 @default.
- W2536704472 hasRelatedWork W4232804208 @default.
- W2536704472 hasRelatedWork W59994307 @default.
- W2536704472 hasVolume "22" @default.
- W2536704472 isParatext "false" @default.
- W2536704472 isRetracted "false" @default.
- W2536704472 magId "2536704472" @default.
- W2536704472 workType "article" @default.